Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-α activity in human immunodeficiency virus type 1 infection

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 913-923

  Aukrust, Pål ^a   Hestdal, Ketil ^b   Lien, Egil ^b   Bjerkeli, Vigdis ^b   Nordey, Ingvild ^b   Espevik, Terje ^b   Müller, Fredrik ^b   Frøland, Stig S ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0030840408     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516510     Document Type: Article

References (14)

1. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1:355-7.
2. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D. Variatioṅ in the TNF-α promotor region associated with susceptibility to cerebral malaria. Nature 1994;371:508-11.
3. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
4. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-8.
5. Dalgleish AG. The immune response to HIV: potential for immunotherapy? Immunol Today 1995; 16:356-8.
6. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-17.
7. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection. Correlation to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169:420-4.
8. Godfried MH, van der Poll T, Weverling GJ, et al. Soluble receptors for tumor necrosis factor as predictor of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994; 169:739-45.
9. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
10. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-43.
11. Achiron A, Margalit R, Hershkoviz R, et al. Intravenous immunoglobulin treatment of experimental T-cell-mediated autoimmune disease. J Clin Invest 1994;93:600-5.
12. Yap PL. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol 1994;97(suppl 1):59-67.
13. Pahwa S. Intravenous immune globulin in patients with acquired immune deficiency syndrome. J Allergy Clin Immunol 1989;84:625-31.
14. + lymphocyte decline in HIV infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr 1993;6:1103-13.